MANGOCEUTICALS, INC. Files 8-K on Security Holder Rights

Ticker: MGRX · Form: 8-K · Filed: Oct 11, 2024 · CIK: 1938046

Mangoceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyMangoceuticals, INC. (MGRX)
Form Type8-K
Filed DateOct 11, 2024
Risk Levellow
Pages6
Reading Time8 min
Key Dollar Amounts$0.0001, $1.00 m, $1.00
Sentimentneutral

Sentiment: neutral

Topics: corporate-event, filing

TL;DR

MANGOCEUTICALS, INC. filed an 8-K on Oct 8th about changes to security holder rights.

AI Summary

On October 8, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing material modifications to security holder rights and other events. The company, incorporated in Texas with its principal executive offices in Dallas, reported its fiscal year ends on December 31st. This filing was made on October 11, 2024.

Why It Matters

This 8-K filing indicates potential changes affecting MANGOCEUTICALS, INC. security holders, requiring their attention to understand the implications.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting routine corporate events and does not appear to contain immediate negative financial news.

Key Players & Entities

FAQ

What specific material modifications were made to the rights of security holders?

The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the excerpt.

What is the exact date of the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on October 8, 2024.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on October 11, 2024.

In which state was MANGOCEUTICALS, INC. incorporated?

MANGOCEUTICALS, INC. was incorporated in Texas.

What is the company's principal executive office address?

The company's principal executive office is located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.

Filing Stats: 1,912 words · 8 min read · ~6 pages · Grade level 12.5 · Accepted 2024-10-11 17:15:11

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: October 11, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing